Fulgent Genetics Inc. (FLGT) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Fulgent Genetics Inc. (FLGT)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

17.17

-0.77 (-4.29%)

At close: Jan 14, 2025, 3:59 PM

17.13

-0.23%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	16.99
Market Cap	525.18M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.52
PE Ratio (ttm)	-3.11
Forward PE	n/a
Analyst	Hold

Ask	18.1
Volume	292,791
Avg. Volume (20D)	246,313
Open	18.04
Previous Close	17.94
Day's Range	16.88 - 18.04
52-Week Range	16.56 - 27.56
Beta	undefined

About FLGT

Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children i...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Sep 29, 2016

Employees 1,184

Stock Exchange NASDAQ

Ticker Symbol FLGT

Website https://www.fulgentgenetics.com

Analyst Forecast

According to 1 analyst ratings, the average rating for FLGT stock is "Hold." The 12-month stock price forecast is $22, which is an increase of 28.13% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Fulgent Genetics Inc. is scheduled to release its earnings on Feb 26, 2025, before market opens.
Analysts project revenue of $75.39M, reflecting a 6.93% YoY growth and earnings per share of -0.37, making a -232.14% decrease YoY.

Why Price Moved

10 months ago · Source

-8.12%

Fulgent Genetics shares are trading lower after th... Unlock content with Pro Subscription

News

3 weeks ago · seekingalpha.com

Fulgent Genetics: High Insider Ownership Supports Asymmetric Upside

1 month ago · zacks.com

Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know

The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 31.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...

1 month ago · zacks.com

All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy

Fulgent Genetics (FLGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 month ago · zacks.com

New Strong Buy Stocks for November 22nd

SNEX, PKG, APAM, MNDY and FLGT have been added to the Zacks Rank #1 (Strong Buy) List on November 22, 2024.

2 months ago · seekingalpha.com

Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript

Fulgent Genetics, Inc. (NASDAQ:FLGT ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Melanie Solomon - Investor Relations Ming Hsieh - Chairman, Chief Executive Offi...

2 months ago · zacks.com

Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates

Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.39 per share a year ag...

2 months ago · businesswire.com

Fulgent Reports Third Quarter 2024 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeuti...

2 months ago · businesswire.com

Fulgent to Participate in Upcoming Conferences

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...

2 months ago · zacks.com

Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?

Fulgent Genetics (FLGT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc...

2 months ago · businesswire.com

Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1

2 months ago · businesswire.com

Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic...